Global Solid Tumors Drugs Market 2016-2020
- Published: Jun 2016
- Pages: 156
- SKU: IRTNTR9801
Enjoy complimentary customisation on priority with our Enterprise License!
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
This market research study identifies Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, and BMS as the leading vendors in the global solid tumors drugs market. A comprehensive study of this market is also presented by molecule type, by therapy, by disease, and by geography. This report also provides an in-depth analysis of the key growth drivers and trends influencing the market.
Overview of the global solid tumors drugs market
According to the solid tumors drugs industry analysis, this market is projected to witness staggering growth and will post an impressive CAGR of more than 8% over the forecast period. The growing incidence of solid tumors worldwide has resulted in pharmaceutical companies investing heavily in R&D to provide more efficacious and better-tolerated medications. The clinical pipeline for solid tumors is vast, featuring drugs in different stages of development. Moreover, many companies are set to launch 2 to 3 new drugs, which are now in the pipeline, during the forecast period. Around 30% of all biologics awaiting the US FDA’s approval are monoclonal antibodies for the treatment of solid tumors. Some of these drugs include Elotuzumab, Avelumab, and biosimilars of Avastin, MabThera, and Herceptin. Besides these, some molecules are in Phase I/II, pre-clinical, and discovery stages, which will form a robust pipeline for solid tumors in the coming years.
The emergence of biosimilars is one of the emerging solid tumors drugs market trends spurring the growth prospects for this market during the forecast period. Biosimilars, unlike generic drugs, are almost similar to the originator biologic compounds. When developed by different manufacturers, these drugs can differ from the original product, as well as from each other. Also, they cost less than biologics and are therefore more accessible to patients. Some of the major biologics available for the treatment of solid tumors include MabThera, Avastin, Herceptin, Erbitux, and Vectibix. However, patent expiries of the major biologics will result in the emergence of the biosimilars of these drugs. The sales of these biologics may decline during the forecast period due to growth in the sales of their biosimilar versions.
Segmentation by molecule type and analysis of the solid tumors drugs market
- Small molecules
- Biologics
During 2015, the biologics segment dominated the market and accounted for close to 59% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
Geographical segmentation and analysis of the solid tumors drugs market
- Americas
- APAC
- EMEA
Based on the solid tumors drugs industry outlook, the Americas dominated the global solid tumors drugs market and is expected to reach more than USD 43 billion by 2020. The growth of this market in the Americas is attributed to the increasing uptake of existing biologics drugs and the launch of new biologics. However, the revenue from these drugs will decrease during the forecast period because of the loss of patent exclusivity of drugs, leading to the entry of generics. This decline is expected to be partially offset by favorable reimbursement plans by the government, such as the provision of Medicare and Medicaid. The US is the largest revenue contributor in this region. The market in the US will grow during the forecast period because of the introduction of novel drugs, which will lead to the vendors earning substantial revenue.
Competitive landscape and key vendors
The competition in the global solid tumors drugs market is intense due to the presence of numerous small and large vendors that operate on a local and global scale. New players are also looking to explore the market because of the growth opportunities. The companies that manufacture and market safe and effective solid tumors drugs are expected to gain a competitive edge over its peers.
Key vendors in this market are
- Hoffmann-La Roche
- Novartis
- Celgene
- Johnson & Johnson
- Pfizer
- BMS
Other prominent vendors in the market are AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BMS, Boehringer-Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford BioTherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, XBiotech, and Zymeworks.
Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the global solid tumors drugs market?
- What are the key market trends impacting the growth of the global solid tumors drugs market?
- What are the challenges to market growth?
- Who are the key vendors in the global solid tumors drugs market?
- What are the market opportunities and threats faced by the vendors in the global solid tumors drugs market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global solid tumors drugs market?
Technavio also offers customization on reports based on specific client requirement.
Related reports:
Table of Contents
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Assumptions
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
- Markers used for diagnosis of solid tumors
PART 05: Cost analysis
PART 06: Pipeline portfolio
- Anticipated number of products with single and multiple indications by 2020
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by molecule type
- Small molecules
- Biologics
PART 09: Market segmentation by type of therapy
- Chemotherapy
- Hormone therapy
- Targeted therapy
- Immunotherapy
PART 10: Market segmentation by disease
- Global breast cancer drugs market
- Global NHL drugs market
- Global colorectal cancer drugs market
- Global NSCLC drugs market
- Global prostate cancer drugs market
- Global kidney cancer drugs market
- Global retinoblastoma drugs market
- Global cervical cancer market
- Global melanoma drugs market
- Global gastric cancer drugs market
- Global pancreatic cancer drugs market
- Global ovarian cancer drugs market
- Global liver cancer drugs market
- Global HL drugs market
- Global glioblastoma multiforme drugs market
PART 11: Geographical segmentation
- Solid tumors drugs market in Americas
- Solid tumors drugs market in EMEA
- Solid tumors drugs market in APAC
PART 12: Market drivers
- Patient assistance programs
- Exposure to risk factors
- Provision for rare diseases
- Promising pipeline
- Increase in prevalence of solid tumors
PART 13: Impact of drivers
PART 14: Market challenges
- Patent expiration of top-selling drugs
- Poor diagnosis and screening
- High cost of drugs
- Availability of chemotherapy and off-label drugs
- Stringent regulations
PART 15: Impact of drivers and challenges
PART 16: Market trends
- Increase in cancer awareness
- Emergence of targeted and combination therapies
- Emergence of biosimilars
- Joint ventures and partnerships for R&D
- Increase in use of brachytherapy
PART 17: Vendor landscape
- Competitive scenario
- Market share analysis 2015
- F. Hoffmann-La Roche
- Novartis
- Celgene
- Johnson & Johnson
- Pfizer
- BMS
- Other prominent vendors
PART 18: Appendix
- List of abbreviations
PART 19: Explore Technavio
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases

DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts

REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
